Takayasu Arteritis: Recent Developments

Curr Rheumatol Rep. 2019 Jul 18;21(9):45. doi: 10.1007/s11926-019-0848-3.

Abstract

Purpose of review: Takayasu arteritis (TA) is a granulomatous inflammatory disorder that affects large vessels, especially aorta and its proximal branches. Its diagnosis can be extremely challenging due to the non-specificity of the systemic inflammatory manifestations during the early phase of the disease and usually follows an insidious clinical course until the emergence of vascular ischemic complications.

Recent findings: Its pathogenesis has been better delineated in recent years, especially the role of HLA-B*52 allele in certain ethnic groups, as well as the use of biological therapy, and surgical revascularization. Recent findings are discussed in depth. Clinical and epidemiological aspects of TA, recent developments in pathogenesis, and therapy are presented.

Keywords: Aortitis; Biologic therapy; Granulomatous disease; Imaging studies; Surgical revascularization; Vasculitis.

Publication types

  • Review

MeSH terms

  • Angiography
  • Angioplasty
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use*
  • Computed Tomography Angiography
  • Endovascular Procedures
  • Glucocorticoids / therapeutic use*
  • HLA-B52 Antigen / genetics
  • HLA-B52 Antigen / immunology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Magnetic Resonance Angiography
  • Positron Emission Tomography Computed Tomography
  • Rituximab
  • Stents
  • Takayasu Arteritis / diagnosis
  • Takayasu Arteritis / genetics
  • Takayasu Arteritis / therapy*
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • Ultrasonography
  • Vascular Grafting
  • Vascular Surgical Procedures*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Glucocorticoids
  • HLA-B52 Antigen
  • Immunosuppressive Agents
  • Tumor Necrosis Factor Inhibitors
  • Rituximab
  • tocilizumab